And following on, any patient requests to continue with the medication will inevitably be futile and useless.
FDA are highly unlikely to approve the medication (imo) which means there will be no government or insurer subsidy, and private script will be the only way forward, which affects pricing which means the pharma can't survive, which means they will inevitably stop producing the drug.
Again, the sound of inevitability.
ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-135
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.02 |
Change
-0.370(1.91%) |
Mkt cap ! $2.478B | |||
| Open | High | Low | Value | Volume |
| $19.55 | $19.65 | $18.88 | $1.692M | 88.28K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 170 | $19.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.03 | 4 | 1 |
View Market Depth
| Last trade - 10.36am 31/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |